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Abstract; 
Objectives; To determine the outcome of oral progesterone therapy in prevention of preterm labor at a tertiary 
care hospital. Material and methods; All women (345) with previous history of preterm delivery, aged less than 
45 years of age having their gestational ages 15 – 20 weeks were included from January 2018 to May 2019 at 
Department of Gynecology and Obstetrics, Nishtar Hospital Multan. These study cases were given 400 mg oral 
progesterone every day till delivery and were followed till delivery to record prevention of preterm birth 
(efficacy; birth of a baby with more than 37 weeks gestational age assessed on LMP treated with oral 
progesterone). Data were analyzed by using SPSS Version 20. Results; Mean age of our study cases was 30.12 ± 
4. 83 years. Mean parity of our study cases was 4.52 ± 1.19. Mean gravidity of our study cases was 5.66 ± 1.18. 
Mean gestational age of our study cases was 37.51 ± 1.34 weeks at the time of delivery. Mean body mass index 
of our study cases was 23.39 ± 2.87 kg/m2. Our study results have indicated that obesity was present in 83 
(24.1%) study cases. Of these 345 study cases, 180 (52.2%) belonged to urban areas, 328 (95.1%) had singleton 
pregnancy and previous no. of preterm births ranging from 1 – 2 was noted in 240 (69.57%).  Treatment with 
oral progesterone prevented preterm labor in 231 (67%) of the study cases. Conclusion; Our study results 
support the use of oral progesterone as use of oral progesterone was successful in preventing preterm labor in our 
study. Its use was found to be safe and reliable, hence can be given to the women with previous history of 
preterm birth without any adverse side effect. The prevention of preterm birth was significantly associated with 
age, parity, gravidity, no. of previous preterm births, order of pregnancy and residential status. 
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Introduction; 
Preterm births are most commonly reported issue in mother-child health all over the world1.  Preterm births 
complicate 1 in eight births among developed nations and is responsible for approximately 90 % perinatal 
morbidities and mortalities2, 3.  Efforts regarding prevention of preterm births have largely been failed, even 
though there is tremendous level of obstetrician efforts involved to specify such patients at risk of preterm births 
were up to the mark in terms of measurement of transvaginal cervical length and cervicovaginal fetal fibrinogen 
testing 4. 
Prevention of PTB, in recent healthcare services, has been most important desiderate in obstetrics and a necessity 
of society, however achievement of these goals remains elusive so far. Since 1970s, progesterone is being used 
for the prevention of preterm deliveries, however earlier evidences generated were fraught by mixed findings as 
well as were also based upon results of the underpowered studies, having weak methodologies particularly for 
eligibility criteria. These evidences also included history of spontaneous abortion as a treatment indication 5.  
Recently, use of progesterone has again emerged as potential pharmacological treatment modality for the 
improvement of pregnancy outcomes among population subsets who are at increased risk of preterm labor. 
During pregnancy, use of endogenous steroid hormones has been well established for the regulation of endocrine 
pathways. Estrogens have the potential to help sustain pregnancy to its full terms as well as termination of 
pregnancy by initiation of labor. Estrogens can help maintain the pregnancy by promoting their ability to 
synthesize progesterone6. Progesterone is primarily responsible for maintaining pregnancy across the various 
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phenomenon such as morphological changes of the cervix and myometrium, inhibits uterine contractions and 
also down regulation of immune system systematically as well as maternal fetal interface 7-12. A study conducted 
by Ibrahim et al10 concluded that progesterone prevented preterm labor in 68 % of the women with previous 
history of preterm labor.  Mean gestational age was 37.47 ± 1.55 weeks in their study cases. Another study 
conducted by Ahmed et al11 reported prevention of preterm labor in 66% pregnant ladies with previous history of 
preterm deliveries. 
 This proposed study is done to document the frequency of prevention of preterm labor after treated with 
oral progesterone to draw evidence from our population regarding efficacy of oral progesterone to prevent 
preterm birth.  
 
Material and methods 
All women (345) with previous history of preterm delivery, aged less than 45 years of age having their 
gestational ages 15 – 20 weeks were included from January 2018 to May 2019 at Department of Gynecology and 
Obstetrics, Nishtar Hospital Multan.  Patients with history of regular uterine contractions, scarred uterus and 
presence of fetal anomalies, diabetes, UTI and pre-eclampsia were excluded from our study. Once registered 
these study cases were arranged for all baseline investigations including ultrasonography. These study cases 
were given 400 mg oral progesterone every day till delivery and were followed till delivery to record prevention 
of preterm birth (efficacy; birth of a baby with more than 37 weeks gestational age assessed on LMP treated with 
oral progesterone). Data were analyzed by using SPSS Version 20. Mean and standard deviation was calculated 
for the numerical data like age of patients, gravidity, parity and gestational age. Frequencies and percentages 
were tabulated for qualitative variables like age groups, preterm labor and type of pregnancy 
(singleton/multiple).    
 
Results; 
Our study comprised of a total of 345 pregnant women with previous history of preterm labor who met 
inclusion criteria of this study. Mean age of our study cases was 30.12 ± 4. 83 years (range 22 – 41 years) and 
179 (51.9%) had their age ranging from 20 – 30 years. Mean parity of our study cases was 4.52 ± 1.19 (with 
minimum parity was 3 while maximum was para 7) and majority of these women i.e. 228 (66.1%) belonged to 
the group having parity 3 – 5. Mean gravidity of our study cases was 5.66 ± 1.18 (with minimum gravidity was 4 
while maximum with gravidity 8) and most of the ladies i.e. 199 (57.7%) had gravidity equal to or less than 5. 
Mean gestational age of our study cases was 37.51 ± 1.34 weeks at the time of delivery (with minimum 
gestational age was 32 weeks while maximum was 39 weeks).  Mean body mass index of our study cases was 
23.39 ± 2.87 kg/m2 (with minimum BMI was 20.5 while maximum was 31 kg/m2). Mean height was 152.09 ± 
10.66 centimeters while mean weight of our study cases was noted to be 52.38±7.40 kilograms. Our study results 
have indicated that obesity was present in 83 (24.1%) study cases. Of these 345 study cases, 180 (52.2%) 
belonged to urban areas, 328 (95.1%) had singleton pregnancy and previous no. of preterm births ranging from 1 
– 2 was noted in 240 (69.57%).  Treatment with oral progesterone prevented preterm labor in 231 (67%) of the 
study cases. 
 
Discussion;  
Oral progesterone is being widely used among pregnant women due to its therapeutic application to prevent 
preterm births, recurrent miscarriages and treatment of threatened pregnancies 13-15. Progesterone has got the 
capability to quiet the gravid uterus which ultimately allows pregnancy to physiologically attain full term in a 
natural way16. It bears ability to block impacts of oxytocin in terms of prostaglandin F2 [alpha] and [alpha]-
adrenergic stimulation and therefore increases the [alpha]-adrenergic tocolytic response when it is in sufficient 
levels in the myometrium 17, 18.  
Our study comprised of a total of 345 pregnant women with previous history of preterm labor who met 
inclusion criteria of this study. Mean age of our study cases was 30.12 ± 4. 83 years (with minimum age was 22 
years while maximum age was 38 years). Our study results have indicated that majority of our study cases i.e. 
179 (51.9%) had their age ranging from 20 – 30 years. Similar results have been reported by Ibrahim et al 10.  
Ahmed et al 11 27.42 ± 3.84 years mean age which is similar to that of our study results. Meis et al 19 reported 
mean age to be 26.0 ± 5.6 years which is close to our study results. Mean parity of our study cases was 4.52 ± 
1.19 (with minimum parity was 3 while maximum was para 7) and majority of these women i.e. 228 (66.1%) 
belonged to the group having parity 3 – 5. Our findings are in compliance with that of Meis et al 19. Mean 
gravidity of our study cases was 5.66 ± 1.18 (with minimum gravidity was 4 while maximum with gravidity 8) 
and most of the ladies i.e. 199 (57.7%) had gravidity equal to or less than 5. Ibrahim et al 10 reported 3.96 ± 1.04 
which is close to our study results.   
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Mean gestational age of our study cases was 37.51 ± 1.34 weeks (with minimum gestational age was 32 
weeks while maximum was 39 weeks).  Ibrahim et al 10 reported 37.47 ± 1.55 week which is similar to that of 
our study results. Meis et al 19 reported similar results. Mean body mass index of our study cases was 23.39 ± 
2.87 kg/m2 our study results have indicated that obesity was present in 83 (24.1%) study cases. Of these 345 
study cases, 180 (52.2%) belonged to urban areas, 328 (95.1%) had singleton pregnancy and previous no. of 
preterm births ranging from 1 – 2 was noted in 240 (69.57%). Meis et al 19 reported 26.9 ± 7.9 kg/m2 BMI, 
considering BMI values in American population, these findings are close to our study results.  
  Progesterone is a necessary steroid hormone required in the endocrinological milieu of females that 
plays essential roles in various phases of human reproduction. Its roles include the proper regulation of menstrual 
cycle, embryo implantation and pregnancy maintenance until term. Treatment with oral progesterone prevented 
preterm labor in 231 (67%) of the study cases. Rai et al 20 reported 61 % prevention of preterm birth with oral 
progesterone. These findings are close to our study results. A study conducted by Ibrahim et al10 concluded that 
progesterone prevented preterm labor in 68 % of the women with previous history of preterm labor.  Mean 
gestational age was 37.47 ± 1.55 weeks in their study cases. Another study conducted by Ahmed et al11 reported 
prevention of preterm labor in 66% pregnant ladies with previous history of preterm deliveries. Meis et al 19 
reported 64 % prevention of preterm birth which is again close to our study results.  
 
Conclusion; 
Our study results support the use of oral progesterone as use of oral progesterone was successful in 
preventing preterm labor in our study. Its use was found to be safe and reliable, hence can be given to the women 
with previous history of preterm birth without any adverse side effect. The prevention of preterm birth was 
significantly associated with age, parity, gravidity, no. of previous preterm births, order of pregnancy and 
residential status. 
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